FDA Confirms SeaStar Medical Has Fulfilled the Post-Approval Study Requirements for QUELIMMUNE® for the Treatment of Sepsis-Associated Acute Kidney Injury (AKI) in Pediatric Patients

FDA clears post-approval study for QUELIMMUNE, confirming significant survival benefit in pediatric AKI.

What the company is saying

SeaStar Medical announces that the FDA’s Center for Biologics Evaluation and Research has determined the QUELIMMUNE Pediatric SAVE Surveillance Registry has fulfilled all post-approval study requirements under the original Humanitarian Device Exemption for QUELIMMUNE. The company frames this as a major regulatory milestone enabling broader hospital access to QUELIMMUNE therapy for critically ill children with sepsis-associated acute kidney injury (AKI) requiring renal replacement therapy. CEO Eric Schlorff emphasizes the potential to expand life-saving benefits, citing a typical 50% survival rate for these children with standard care. The announcement highlights statistically significant clinical results, including improved 90-day survival, and stresses the absence of device-related adverse events. Chief Medical Officer Kevin Chung underscores the severity of the patient population and the value of real-world evidence from the SAVE Registry. The company also notes that QUELIMMUNE has been adopted by leading children’s medical centers and reiterates ongoing voluntary data collection.

What the data suggests

The SAVE Registry data, presented at ASN Kidney Week 2026, show a 90-day survival rate of 65.1% for QUELIMMUNE (SCD-PED) patients (N=43), compared to 47.5% for matched cohorts from the Kids’ Inpatient Database (N=196), with a statistically significant P value of 0.043. No device-related adverse events were reported among registry patients. Additional clinical trial data published in Kidney Medicine reported a 77% survival rate for QUELIMMUNE-treated patients, representing an approximate 50% reduction in loss of life versus historical controls. Among survivors, 87.5% had normal kidney function at Day 60 post-ICU discharge, and none required dialysis. The therapy is approved for children aged ≤22 years, weighing at least 10 kg, with AKI and sepsis or septic condition on antibiotics and ICU RRT. The NEUTRALIZE-AKI pivotal trial is ongoing in 339 adults, targeting a population of over 200,000 affected annually in the U.S. While the clinical and regulatory data are robust, there are no disclosed figures on revenue, adoption rates, or commercial performance.

Analysis

The announcement is generally positive and well-supported by clinical and regulatory milestones: the FDA has confirmed that the SAVE Registry has fulfilled post-approval study requirements, and statistically significant survival benefits are disclosed with supporting numerical data. Most key claims are realised and substantiated, including FDA approval, clinical trial results, and the therapy's commercial availability for pediatric AKI. However, some language inflates the signal, such as broad statements about expanding access and adoption by 'many of the highest rated children’s medical centers,' without quantitative adoption data. Forward-looking statements about long-term organ recovery and elimination of future dialysis are speculative and not directly supported by the disclosed evidence. There is no mention of large capital outlays or delayed benefit realisation, and the benefits of the regulatory milestone are immediate, as hospitals can now use the therapy without prior research infrastructure. The absence of financial metrics (revenue, profit, adoption rates) limits the signal to weak_positive, as investors cannot assess commercial traction or profitability.

Risk flags

• ●Commercial adoption risk remains, as the announcement provides no quantitative data on current hospital uptake, sales, or revenue, making it unclear how quickly or widely QUELIMMUNE will be used beyond the initial centers.
• ●Long-term safety and efficacy in broader real-world settings are not yet established, as ongoing voluntary data collection may reveal new adverse events or less favorable outcomes outside controlled trial environments.
• ●The NEUTRALIZE-AKI pivotal trial in adults is still in progress, so any extension of the therapy’s label or market size depends on future results that are not yet available.
• ●The therapy requires use with citrate anticoagulation and carries risks such as hypotension, hypothermia, tachycardia, hyperglycemia, thrombocytopenia, blood loss, or extracorporeal circuit complications, which could limit adoption or trigger regulatory scrutiny if adverse events emerge.
• ●No financial metrics, such as revenue, cost, or margin data, are disclosed, preventing assessment of the therapy’s commercial viability or the company’s financial health.

Bottom line

SeaStar Medical has achieved a key regulatory milestone, with the FDA confirming that its post-approval study obligations for QUELIMMUNE have been met, immediately enabling broader hospital access for pediatric AKI patients. The disclosed clinical data show a clear and statistically significant survival benefit—65.1% 90-day survival versus 47.5% for historical controls, and 77% survival in prior trials, with 87.5% of survivors regaining normal kidney function. No device-related adverse events were reported in the registry. However, the announcement does not provide any financial or adoption figures, so the scale of commercial impact and revenue potential remains uncertain. Investors should focus on future disclosures of sales, adoption rates, and adult trial results to gauge the therapy’s market traction and financial upside. The most important takeaway is that QUELIMMUNE is now more accessible to critically ill children, but the investment case will depend on evidence of commercial uptake and sustained clinical performance.

Announcement summary

(NASDAQ:ICU) SeaStar Medical Holding Corporation announced that the Center for Biologics Evaluation and Research (CBER) of the U.S. Food and Drug Administration (FDA) has determined that the QUELIMMUNE Pediatric SAVE Surveillance Registry (SAVE Registry) has fulfilled the post-approval study requirements as outlined in the original Humanitarian Device Exemption (HDE) approval of QUELIMMUNE. Eric Schlorff, CEO of SeaStar Medical, stated that this decision will enable the company to expand the potential life-saving benefits of QUELIMMUNE therapy to more critically ill children with life-threatening acute kidney injury (AKI). Children with life-threatening AKI typically have about a 50% survival rate with traditional supportive care alone. Results from the SAVE Registry were presented at ASN Kidney Week 2026, highlighting a clinically meaningful and statistically significant improvement in 90-day survival of 65.1% for QUELIMMUNE (SCD-PED) patients (N=43) compared to 47.5% for patients from the Kids’ Inpatient Database (KID) (N=196), with a P value of 0.043. No device-related adverse events were reported in the SAVE Registry patients. Statistically significant increases for both in-hospital and 60-day survival were also observed for patients treated with QUELIMMUNE (SCD-PED) compared to KID cohorts. KID is the largest publicly available, all-payer pediatric inpatient care database in the United States. Kevin Chung, MD, Chief Medical Officer of SeaStar Medical, emphasized the importance of the SAVE Registry in providing real-world evidence on safety and probable benefits in these patients. FDA’s decision now allows hospitals to use QUELIMMUNE therapy without the research infrastructure previously required by the SAVE Registry, expanding access to critically ill pediatric patients with sepsis-associated AKI on renal replacement therapy (RRT). SeaStar Medical will continue to voluntarily enroll patients in the SAVE Registry at participating medical centers. The QUELIMMUNE therapy has been adopted by many of the highest rated children’s medical centers in the United States. The patented technology behind QUELIMMUNE is known as the Selective Cytopheretic Device (SCD) therapy. QUELIMMUNE (SCD-PED) therapy is commercialized for children with AKI and sepsis or septic condition weighing 10 kilograms or more and aged ≤22 years who are on antibiotics and being treated in the ICU with RRT. QUELIMMUNE was approved in February 2024 under a Humanitarian Device Exemption application. Data from two clinical trials published in Kidney Medicine showed a 77% survival rate in patients treated with QUELIMMUNE versus standard of care, representing an approximate 50% reduction in loss of life compared to historical data. No dialysis was required for survivors, and 87.5% of survivors had normal kidney function at Day 60 after ICU discharge. QUELIMMUNE was approved by FDA under a Humanitarian Device Exemption based on safety and probable benefit. Adverse reactions observed in clinical studies include hypotension, hypothermia, tachycardia, hyperglycemia, and thrombocytopenia, with additional risks including blood loss or extracorporeal circuit complications. QUELIMMUNE must be used with citrate anticoagulation. The NEUTRALIZE-AKI pivotal trial is evaluating the safety and efficacy of the SCD therapy in 339 adults with AKI in the ICU receiving continuous renal replacement therapy (CRRT), with a primary endpoint of a composite of 90-day mortality or dialysis dependency. Secondary endpoints include mortality at 28 days, ICU-free days in the first 28 days, major adverse kidney events at Day 90, and dialysis dependency at one year. The study will also include subgroup analyses for AKI patients with sepsis and acute respiratory distress syndrome. SeaStar Medical’s SCD therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA. The company is currently conducting the NEUTRALIZE-AKI pivotal clinical trial in adult patients with AKI requiring continuous RRT, a condition that impacts over 200,000 adults in the United States annually.

Disagree with this article?